Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Andrea Wang-GillamRamaswamy Govindan

Abstract

Activation of clinical trials is a lengthy process. We studied the procedures and time required to activate lung cancer clinical trials in a US academic center compared with a European center. A retrospective review was performed of all thoracic oncology therapeutic trials submitted for regulatory review between 2001 and 2008 at Washington University School of Medicine (WUSM; St Louis, MO) and the University of Torino (UT; Torino, Italy). A process map was drafted by both institutions to establish the order of required events. We reviewed 137 therapeutic thoracic oncology trials from WUSM (n = 83) and UT (n = 54). The median times from submission to opening a trial were 163 days for WUSM and 112.5 days for UT (P = .048). The median times for regulatory approval were 75 days for WUSM and 31 days for UT (P < .001). The difference is more pronounced in a homogeneous subset of phase II, industrial-sponsored trials for the median calendar time from submission to opening a trial (239.5 days for WUSM v 112.5 days for UT; P < .001) and time for regulatory approval (99 days for WUSM v 13.5 days for UT; P < .001). The median number of patients accrued at WUSM was 7.4 patients per study compared with an average of 37 patients per study at...Continue Reading

References

Mar 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P N LaraK S Lam
Mar 19, 2003·International Journal of Health Services : Planning, Administration, Evaluation·Sonia Shah
May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN American Society of Clinical Oncology
May 27, 2005·The New England Journal of Medicine·Michelle M MelloDavid M Studdert
Sep 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karl T Hagler, James W Lynch
Sep 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David M Dilts, Alan B Sandler
Sep 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David M DiltsUNKNOWN Case of Cancer and Leukemia Group B
Jun 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David M DiltsRobert Comis
Nov 27, 2008·Nature Clinical Practice. Oncology·Vincent T DeVita
Feb 21, 2009·The New England Journal of Medicine·Seth W GlickmanKevin A Schulman
Oct 21, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Todd H WagnerJeffrey Abrams
Aug 5, 2010·Journal of the National Cancer Institute·John F Scoggins, Scott D Ramsey

❮ Previous
Next ❯

Citations

Feb 9, 2012·American Journal of Clinical Oncology·Samantha CaldwellGlen J Weiss
Nov 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David M DiltsJames H Doroshow
Feb 26, 2016·Trials·Diego A MartinezBenjamin Djulbegovic
Apr 23, 2011·Forensic Science International : Synergy·V PirroA Salomone
Dec 31, 2015·Journal of the National Cancer Institute·Derek Raghavan
Jul 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David M Dilts
Feb 13, 2014·American Journal of Clinical Oncology·Nancy R RutherRonald S Go
Dec 20, 2011·Journal of the Royal Society of Medicine·Zoë Slote MorrisJonathan Grant
Feb 7, 2018·International Journal of Technology Assessment in Health Care·Gianpiero FasolaGuglielmo Pacileo
Mar 21, 2017·The Oncologist·Arthur E FrankelEugene P Frenkel
Jun 3, 2020·Clinical Pharmacology and Therapeutics·Sarah A Holstein, Julie M Vose
Jul 2, 2014·Clinical Trials : Journal of the Society for Clinical Trials·Scott R RosasJonathan M Kagan
Mar 1, 2013·Therapeutic Innovation & Regulatory Science·Diana AbbottSwati Chakraborty
Oct 11, 2013·Experimental Biology and Medicine·Valentina I PetkovJames H McDermott
Mar 10, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chad TangJ Jack Lee
Nov 18, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chad TangDavid S Hong
Mar 18, 2021·The Oncologist·Gabrielle W PetersKimberly L Johung

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.